Logo
Loading Weather...

Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating

Business March 6, 2026 0 Views
Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating
Source: https://finance.yahoo.com/rss/topstories - Read Original

Discussion (0)

Please log in to post a comment.

No comments yet. Be the first to share your thoughts!